Abstract:PURPOSE Varied therapeutic responses were observed among cancer patients receiving the same treatment regimen, highlighting the challenge of identifying patients most likely to benefit from a given therapy. Here, we present an artificial intelligence-based approach, called CDK4/6 inhibitor Response Model (CRM), to address the complexity of predicting patient responses to treatment by a certain clinical scene on CDK4/6 inhibitors (CDK4/6i).PATIENTS AND METHODS To train the CRM, we transformed the genomic data of 980 breast cancer patients from the TCGA database into activity profiles of signaling pathways (APSP) by utilizing the modified Damage Assessment of Genomic Mutations (DAGM) algorithm. A scoring model was then established by random forest algorithm to classify the HR+/HER2− and HR−/HER2− breast cancer molecular subtypes by the differential APSP features between the two, which reasonably reflected the potential role played by CDK4/6 molecules in HR+/HER2− breast cancer cells. The effectiveness of CRM was then tested in a separate local patient cohort (n = 343) in Guangdong, China. Twin in-silico clinical trials (ICT) of previously disclosed clinical trials ([NCT02246621][1], [NCT02079636][2], [NCT03155997][3], [NCT02513394][4], [NCT02675231][5]) were performed to demonstrate the potential of CRM in generating concerted results as the real-world clinical outcomes.RESULTS The CRM displayed high precision in classifying HR+/HER2− and HR−/HER2− breast cancer patients in both TCGA (AUC=0.9956) and local patient cohorts (AUC=0.9795). Significantly, the scores were distinct (p = 0.025) between CDK4/6i-treated patients with different responses. Breast cancer patients from different subtypes were grouped into five distinct populations based on the scores assigned by the CRM. From twin ICT, the CRM scores reflected the differential responses of patient groups to CDK4/6i-based therapies.CONCLUSION The CRM score showed not only a robust association to clinically observed CDK4/6i responses but also heterogenetic responses across subtypes. More than half of HR+/HER2+ patients may be benefited from CDK4/6i-based treatment. The CRM empowered us to conduct ICT on different types of cancer patients responding to CDK4/6i-based therapies. These findings showed the potential of CRM as the companioned ICT to guide CDK4/6i application in the clinical end. CRM-guided ICT could be a universal method to demonstrate drug sensitivity to various patients.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThis work was supported by National Natural Science Foundation of China (grant no. 82072939 to M. Yang), Natural Science Foundation of Guangdong Province (grant no. 2022A1515010425 to M. Yang), Guangzhou Science and Technology Program (grant no. 202206010110 to M. Yang), National Natural Science Foundation of China (grant no. T2125013 to G. Tan), Hefei National Laboratory for Physical Sciences at the Microscale (grant no. KF2020009 to G. Niu).### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Guangdong Provincial People's Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02246621&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02079636&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [3]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03155997&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [4]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02513394&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom [5]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02675231&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F21%2F2023.05.15.23289976.atom

Abstract LB_B19: Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 …

A Genome-Informed Functional Modeling Approach to Evaluate the Responses of Breast Cancer Patients to CDK4/6 Inhibitors-Based Therapies and Simulate Real-World Clinical Trials

Abstract LB_B19: Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients

76P Using bioinformatics and artificial intelligence (AI) to map the cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) translational biomarker landscape

Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Abstract PO4-14-09: A computational model of the mechanisms of action of combined endocrine therapy and CDK4/6 inhibition predicts outcome in patients with Luminal B breast cancer

Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition

Abstract 3537: Assessing machine learning models of drug response predictions using orthotopic patient-derived xenograft

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Prediction of Cancer Patient Responses to Different Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles.

Abstract A066: Machine learning elucidates biology of response within and outside the mechanisms of action of therapeutic agents in the I-SPY2 breast cancer TRIAL

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).

Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy

Gene expression-based machine learning approach to predict immunotherapy response and survival in patients with advanced cancer.

Abstract 4910: AI predicts drug response from the genomic features of cells and the kinase activity changes induced by compounds

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

Abstract P1-08-31: Simbiosys tumorscope: Biophysical modeling of patient-specific response to chemotherapy

Abstract 3982: Prediction and Selection of Cancer Drug Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles

Abstract 6253: Single-cell RNA sequencing reveals metastatic site-specific biomarkers for predicting response to CDK4/6 inhibition in advanced HR+/HER2- breast cancer

Abstract 3287: Learning to target CDK4/6 inhibitor resistance via a breast cancer-specific atlas of cellular mechanisms